Company profile: Prexton Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical drug development focused on innovative drugs to improve quality of life. Swiss-based, founded in 2012 by Francois Conquet and MS Ventures under the Merck Serono Entrepreneur Partnership Program, applying a new scientific approach.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Prexton Therapeutics
SensoDetect
HQ: Sweden
Website
- Description: Provider of medical device technology to help detect mental illness.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SensoDetect company profile →
Mynd Life Sciences
HQ: Canada
Website
- Description: Provider of biomarker diagnostic tests for postpartum depression and early Alzheimer’s detection, psilocybin-based drug R&D targeting central nervous system diseases, and intellectual property on inflammation-regulating gene pathways to support treatments for neuroinflammatory diseases; also developing at-home tests to monitor inflammation and aid health management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mynd Life Sciences company profile →
Landos Biopharma
HQ: United States
Website
- Description: Provider of oral, first-in-class, locally acting small-molecule therapeutics for autoimmune diseases. Pipeline: NX-13 (NLRX1) for ulcerative colitis and Crohn’s; LABP-66 (NLRX1) for multiple sclerosis and neurodegenerative disorders; LABP-73 (NLRX1) for asthma and eosinophilic disorders; LABP-69 (PLXDC2) for rheumatoid arthritis, ulcerative colitis, and Crohn’s.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Landos Biopharma company profile →
Moberg
HQ: United States
Website
- Description: Provider of medical devices and neurodiagnostic solutions, including RetCam Envision pediatric ophthalmic imaging, Otoscan 3D ear scanning for auditory assessments, Natus NeuroWorks EEG analysis software, UltraPro S100 EMG/NCS/EP neurodiagnostic systems, and dedicated service and support for efficient workflows and optimal patient outcomes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Moberg company profile →
NLS Pharmaceutics
HQ: Switzerland
Website
- Description: Provider of clinical-stage drug development focused on neurobehavioral and neurocognitive disorders and their pharmacognosia, using a patient-centered, target-specific approach via collaborations with industry and academia. Products include Quilience, an extended-release mazindol for excessive daytime sleepiness and cataplexy in narcolepsy, and Nolazol, a controlled-release mazindol for ADHD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NLS Pharmaceutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Prexton Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Prexton Therapeutics
2.2 - Growth funds investing in similar companies to Prexton Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Prexton Therapeutics
4.2 - Public trading comparable groups for Prexton Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →